Indian Januvia challenger Aprica harps on price as MSD takes action
This article was originally published in Scrip
Executive Summary
A fledgling Indian company, Aprica Pharmaceuticals, appears to have come close to a potential launch of cut-price versions of MSD's diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride) on the Indian market, prompting pre-emptive legal action from the US multinational.